(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 22 January 2004 (22.01.2004)

(10) International Publication Number

(51) International Patent Classification7:

A61B

WO 2004/006756 A2

(21) International Application Number:

PCT/US2003/022440

(22) International Filing Date:

17 July 2003 (17.07.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/396,393

17 July 2002 (17.07.2002) US

(71) Applicant (for all designated States except US): BIOGEN INC. [US/US]; 14 Cambridge Center, Cambridge, MA 02142 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): LOBB, Roy, R. [US/US]; 569 Canton Street, Westwood, MA 02090 (US).

(74) Agents: CLAUSS, Isabelle, M et al.; Patent Group, Foley Hoag LLP, 155 Scaport Boulevard, Boston, MA 02210 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CII, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THERAPIES FOR RENAL FAILURE USING INTERFERON-β

(57) Abstract: The present invention provides methods for the treatment, and pharmaceuticals for the use in the treatment, of mammalian subjects having, or at risk of developing, glomerulonephritis or chronic renal failure. The methods involve the administration of IFN-B therapeutics.